LifeSci Capital analyst Rahul Rakhit maintained a Buy rating on Akili (AKLI – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1.42.
Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Better Therapeutics, Inc., and Orchestra BioMed Holdings. According to TipRanks, Rakhit has an average return of -50.8% and a 7.14% success rate on recommended stocks.
Currently, the analyst consensus on Akili is a Moderate Buy with an average price target of $3.38.
See the top stocks recommended by analysts >>
Based on Akili’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $113 thousand and a GAAP net loss of $20.71 million. In comparison, last year the company had a GAAP net loss of $4.18 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Social Capital Suvretta Holdings Corp I is a blank check company.
